The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Eisai to Take Over Marketing Rights for Gliadel from Nobelpharma
November 27, 2013
-
ACADEMIA All Clinical Studies Should Follow GCP Requirements: Ex-AZ Chairman Kato
November 26, 2013
-
BUSINESS Farmorubicin Approved for Additional Dosage and Administration for Hepatic Cancer: Pfizer Japan
November 26, 2013
-
BUSINESS AZ Aims to Maintain Presence in Oncology Field Via Partnerships until Launch of New Drugs
November 25, 2013
-
BUSINESS Takeda Deploys Cardiovascular, Diabetes Sales Reps for Comprehensive Detailing Activities for Lifestyle Diseases
November 22, 2013
-
BUSINESS Japan Diovan Sales Down 15.7% in July-September: IMS
November 22, 2013
-
REGULATORY JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
-
BUSINESS Japan Now Part of Global PIII Clinical Study for MLN9708: Takeda
November 21, 2013
-
BUSINESS US Pfizer Plans Simultaneous, Global Filing of Five Biosimilars, Eyes Japan Biosimilar Market Entry
November 20, 2013
-
ACADEMIA JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
November 19, 2013
-
REGULATORY PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29
November 19, 2013
-
BUSINESS Takeda, Eisai Earnings Show Signs of Bottoming Out, on Path to Recovery
November 18, 2013
-
BUSINESS Sales of Major Japanese Drug Makers Soar 8.1% on Weak Yen, Steady Japan Business
November 15, 2013
-
REGULATORY Health Ministry Proposes to Set First Generic Prices at Half of Brand Name Drug Prices
November 14, 2013
-
BUSINESS Otsuka Holdings Notches Double-Digit Sales Growth in April-September, Weaker Yen Comes as Boon
November 14, 2013
-
BUSINESS Generic Market Continues to Grow, Three Generic-Only Makers’ Sales Up 8.8%
November 13, 2013
-
BUSINESS GLP-1 Dulaglutide “Catalyst of Growth,” SGLT-2 Empagliflozin Will Be Successful Despite Later Launch: Lilly Diabetes President
November 12, 2013
-
BUSINESS 4 Major Wholesalers’ Operating Margins Stay on Recovery Path, But Average Settlement Rate at Mere 72% at Sept.-End
November 11, 2013
-
BUSINESS Nichi-Iko Pitting Allegra AG against Other Generics, Not Originator: Pres. Tamura
November 8, 2013
-
REGULATORY “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…